NEW YORK, Sept, 23 /PRNewswire/ — Reportlinker.com announces
that a new market research report is available in its
catalogue:
Multiple Sclerosis (MS) Drugs and Biologics: Technologies and
Global Markets
http://www.reportlinker.com/p0298009/Multiple-Sclerosis-MS-Drugs-and-Biologics-Technologies-and-Global-Markets.html
The total worldwide market for MS disease-modifying therapies is
expected to grow at an 8.1% compound annual growth rate (CAGR) from
2010 through 2015, with sales reaching nearly $16.7 billion by the
end of 2015, from $11.3 billion in 2010.
From 2010 through 2015, the overall small molecule MS
disease-modifying drug market is expected to grow rapidly. This
segment is worth an estimated $3.6 billion in 2010 and is projected
to increase at a 17.4% compound annual growth rate (CAGR) to reach
$7.9 billion in 2015.
Biologics represent the largest class of MS disease-modifying
therapies by sales and by number of approved therapies. This sector
is valued at $7.8 billion in 2010 and is expected to increase at a
2.5% compound annual growth rate (CAGR) to reach a value of $8.8
billion in 2015.
INTRODUCTIONSTUDY GOALS AND OBJECTIVES BCC’s goal in
conducting this study was to determine the current status of the
market for disease-modifying multiple sclerosis (MS) drugs,
biologics, and vaccines and to assess their growth potential over a
5-year period from 2010 through 2015.
MS is an autoimmune disease characterized by the body’s own
immune system attacking itself and causing spots of demyelination
(plaques) in the brain and spinal cord. Symptoms of MS vary widely
depending on th
‘/>”/>
SOURCE
